Additional Information
Market: AIM
Sector: Technology Hardware & Equipment
EPIC: AMP
Latest Price: 4.13p  (0,00%)
52-week High: 7.13p
52-week Low: 2.25p
Market Cap: 5.58M
1 year chart
1 day chart
Watchlist/Portfolio

Add to watchlist:

Only registered members can add into watchlist !

Register here !
Amphion Innovations
www.amphionplc.com

Amphion builds shareholder value in high growth companies in the medical and technology sectors, by using a focused, hands-on company building approach, based on decades of experience in both the US and UK.

Amphion has a significant shareholding in 8 Partner Companies developing proven technologies targeting substantial commercial marketplaces, each in excess of $1 billion. Each Partner Company is chosen with the goal of achieving an exit valuation in excess of $100 million.

Pdf

Amphion Innovations plc Partner Company, DataTern, Signs Three IP License Agreements worth $1.65m

5th May 2009, 7:00 am

London and New York, 5 May 2009 – Amphion Innovations plc (LSE: AMP) (“Amphion”), the developer of medical and technology businesses, today announces that DataTern, Inc., has signed non-exclusive intellectual property license agreements with three leading international corporations for a total of $1.65 million. DataTern has signed seven licenses since it commenced licensing of this product in June 2008, generating total revenues of approximately $7 million. DataTern has now licensed its intellectual property into the financial, credit card, retail, leisure, healthcare, and software industries.

Joseph Flicek, DataTern’s Chief Executive Officer, said, “We have made rapid progress in a relatively short period of time, demonstrating the value that can be extracted from our intellectual property portfolio. We believe there are a large number of potential licensees in a broad spectrum of industries for our IP. Currently, we are in active discussions with six other major corporations and we continue to add to this list.”

DataTern, Inc., wholly owned by Amphion Innovations plc, was established in order to commercialise selected intellectual property opportunities in partnership with Amphion’s Partner Companies.

Richard Morgan, Chief Executive Officer of Amphion, said, “Today’s announcement demonstrates the value that Amphion can generate for its shareholders through monetising our intellectual property. We continue to add further patents and software though the activities of DataTern and our Partner Companies and we look forward to signing further license agreements.”

For further information please contact

Amphion Innovations plc
Charlie Morgan, Director of Communications
+1 (212) 210 6224

Cardew Group
Tim Robertson/ Jamie Milton/ Matthew Law
+44 20 7930 0777

Charles Stanley (Nominated Adviser)
Mark Taylor/ Freddy Crossley
+44 20 7149 6000

About Amphion Innovations plc
Amphion (LSE: AMP) builds shareholder value in high growth companies in the medical and technology sectors, by using a focused, hands-on company building approach, based on decades of experience in both the US and UK. Amphion has a significant shareholding in eight Partner Companies, developing proven technologies targeting substantial commercial marketplaces, each in excess of $1 billion. Each Partner Company is chosen with the goal of achieving an exit valuation in excess of $100 million.

On the web: www.amphionplc.com

About DataTern, Inc.
DataTern owns and develops critical technology that provides next generation software solutions for its customers. DataTern’s patented product offerings include ObjectSpark® Technologies, which allow customers to develop their own customised data service layers, making the company’s offerings valuable to most industries, including automotive, banking, chemical, communications, financial, government, healthcare, insurance, pharmaceutical, trading, and many others. Non-exclusive licenses for DataTern’s technologies and patents are available on reasonable and non-discriminatory terms.

For licensing terms, please contact info@datatern.com.

On the web: www.datatern.com

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.